Scilex Holding Company stock is traded at $1.42, with a volume of 31,981. It is down -8.97% in the last 24 hours and down -50.69% over the past month. Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Previous Close:
$1.56
Open:
$1.55
24h Volume:
31,981
Relative Volume:
0.79
Market Cap:
$9.99M
Revenue:
$33.86M
Net Income/Loss:
-$437.38M
P/E Ratio:
-
EPS:
-$40.58
Net Cash Flow:
-$42.07M
1W Performance:
-16.47%
1M Performance:
-50.69%
6M Performance:
-78.42%
1Y Performance:
-92.05%
1-Day Range:
$1.41$1.57
1-Week Range:
$1.41$1.78
52-Week Range:
$1.41$27.00
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding CompanySector
HealthcareIndustry
Drug Manufacturers - GeneralPhone
(650) 516-4310Address
960 SAN ANTONIO ROAD, PALO ALTO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS